Thus far, no RSV vaccine has been approved in the U.S.
— a reminder of the virus’s threat. Since then, the pharmaceutical race to get vaccines to market has garnered extra attention.
Both shots came with mild to moderate side effects like injection site pain, fatigue and muscle pain.published earlier this month in the New England Journal of Medicine, Graham described Pfizer has also tested a second application of its shot in pregnant people to help protect their infants from RSV. When the vaccine was, the company’s findings suggest it reduced the risk of severe illness in infants by 82% through their first 90 days of life, and 69% through six months. The FDA is reviewing that data and could decide in August whether to approve the shot for pregnant people.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA warns of Guillain-Barre syndrome as possible risk of Pfizer’s RSV vaccineGuillain-Barre syndrome, or inflammatory neuropathy, is a disorder in which the body’s immune system mistakenly attacks the nerves.
Read more »
Pfizer, GSK face FDA panel review in race for RSV vaccinesThe frontrunners in a crowded race to develop the first respiratory syncytial virus (RSV) vaccine - Pfizer Inc and GSK - will face scrutiny from a panel of experts to the U.S. Food and Drug Administration this week.
Read more »
FDA advisors recommend Pfizer RSV vaccine for older adults, despite possible Guillain-Barre risks
Read more »
Paving the way for the world's first RSV vaccine, FDA advisers recommend shot from PfizerBREAKING: FDA advisers recommend that the agency approve the country’s first RSV vaccine for older people, a shot from Pfizer for adults ages 60 and up.
Read more »
FDA panel narrowly backs Pfizer's RSV vaccine for older adultsFederal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against...
Read more »
U.S. FDA panel votes for Pfizer's RSV vaccineA panel of outside advisers to the U.S. Food and Drug Administration (FDA) on Tuesday recommended Pfizer Inc's respiratory syncytial virus (RSV) vaccine, paving the way for one of the first approved RSV shots in the United States for older adults.
Read more »